425: PowerUp Acquisition Corp. Secures Funding to Advance Aspire Biopharma Merger

PowerUp Acquisition Corp. secures a $500,000 loan facility from Blackstone to support its merger with Aspire Biopharma.

Summary

• PowerUp Acquisition Corp. has entered into a subscription agreement, promissory note, and registration rights agreement with Blackstone Capital Advisors, Inc. to secure funding for its business combination with Aspire Biopharma, Inc.
• Blackstone may loan up to $500,000 to PowerUp, subject to a 20% original issue discount.
• As of December 26, 2024, the aggregate principal amount loaned is $184,543.80.
• The promissory note matures on the earlier of June 1, 2025, or when PowerUp receives gross proceeds of at least $5,000,000 from a debt or equity offering.
• The note bears interest at 10% per annum, payable on the maturity date, along with an exit fee of 10% of the principal amount and accrued interest.
• Upon closing of the business combination, the Sponsor will transfer three Class A ordinary shares of PowerUp to Blackstone for each dollar loaned.
• PowerUp has agreed to register these shares with the SEC in connection with a Qualified Offering.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the funding is positive, the terms are somewhat expensive and indicate potential challenges in securing more favorable financing. The reliance on a loan with a high discount and interest rate suggests a degree of financial pressure.

Positives

• PowerUp secures necessary funding to continue pursuing its business combination with Aspire Biopharma.
• The structure of the loan incentivizes Blackstone to support the successful completion of the merger.
• The registration rights agreement provides Blackstone with liquidity options for the shares received.

Negatives

• The loan comes with a significant 20% original issue discount, reducing the net proceeds received by PowerUp.
• The 10% interest rate and 10% exit fee increase the overall cost of capital for PowerUp.
• The transfer of Class A ordinary shares to Blackstone upon closing of the business combination will dilute existing shareholders.

Risks

• The business combination with Aspire Biopharma may not be completed, potentially triggering repayment obligations for PowerUp.
• PowerUp may not be able to raise the required $5,000,000 in debt or equity securities, leading to an earlier maturity date for the loan.
• The value of PowerUp's Class A ordinary shares may decline, impacting the value of the shares transferred to Blackstone.
• The company being delisted from the Nasdaq Capital Market would trigger an event of default.

Future Outlook

The company intends to complete the business combination with Aspire Biopharma. PowerUp may need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all.

Industry Context

This announcement is typical for SPACs seeking to complete a business combination, often requiring additional funding to bridge the gap and finalize the transaction. The terms of the financing reflect the current market conditions for SPACs, with investors demanding higher returns and greater security.

Comparison to Industry Standards

• The terms of the Blackstone loan, including the 20% original issue discount and 10% interest rate, are relatively high compared to traditional debt financing, reflecting the higher risk associated with SPAC transactions.
• Similar SPAC transactions have seen bridge loans with interest rates ranging from 8% to 12%, but the specific terms depend on the target company's profile and the overall market conditions.
• The transfer of Class A ordinary shares to Blackstone is a common practice to incentivize lenders and align their interests with the success of the business combination, similar to earnout provisions in other M&A deals.

Related Party Transactions

• The Blackstone Transaction involves Lance Friedman, Aspire's Director of Investor Relations, indicating a related-party element.

Stakeholder Impact

• Shareholders will experience dilution upon the transfer of Class A ordinary shares to Blackstone.
• The successful completion of the merger could create value for shareholders.
• Employees of Aspire Biopharma may be affected by the integration process following the merger.
• The merger could impact the relationships with customers and suppliers of both PowerUp and Aspire Biopharma.

Next Steps

• PowerUp Acquisition Corp. will seek to complete the business combination with Aspire Biopharma, Inc.
• The company will work to satisfy the conditions for closing the merger, including shareholder approval and regulatory approvals.
• PowerUp will need to manage its cash flow and potentially raise additional capital to meet its financial obligations.
• The company will register the Commitment Shares with the SEC in connection with a Qualified Offering.

Key Dates